Literature DB >> 29046355

Matrix metalloproteinase-7 induces homotypic tumor cell aggregation via proteolytic cleavage of the membrane-bound Kunitz-type inhibitor HAI-1.

Tomohiro Ishikawa1, Yayoi Kimura2, Hisashi Hirano2, Shouichi Higashi3.   

Abstract

Matrix metalloproteinase-7 (MMP-7) plays important roles in tumor progression and metastasis. Our previous studies have demonstrated that MMP-7 binds to colon cancer cells via cell surface-bound cholesterol sulfate and induces significant cell aggregation by cleaving cell-surface protein(s). These aggregated cells exhibit a dramatically enhanced metastatic potential. However, the molecular mechanism inducing this cell-cell adhesion through the proteolytic action of MMP-7 remained to be clarified. Here, we explored MMP-7 substrates on the cell surface; the proteins on the cell surface were first biotinylated, and a labeled protein fragment specifically released from the cells after MMP-7 treatment was analyzed using LC-MS/MS. We found that hepatocyte growth factor activator inhibitor type 1 (HAI-1), a membrane-bound Kunitz-type serine protease inhibitor, is an MMP-7 substrate. We also found that the cell-bound MMP-7 cleaves HAI-1 mainly between Gly451 and Leu452 and thereby releases the extracellular region as soluble HAI-1 (sHAI-1). We further demonstrated that this sHAI-1 can induce cancer cell aggregation and determined that the HAI-1 region corresponding to amino acids 141-249, which does not include the serine protease inhibitor domain, has the cell aggregation-inducing activity. Interestingly, a cell-surface cholesterol sulfate-independent proteolytic action of MMP-7 is critical for the sHAI-1-mediated induction of cell aggregation, whereas cholesterol sulfate is needed for the MMP-7-catalyzed generation of sHAI-1. Considering that MMP-7-induced cancer cell aggregation is an important mechanism in cancer metastasis, we propose that sHAI-1 is an essential component of MMP-7-induced stimulation of cancer metastasis and may therefore represent a suitable target for antimetastatic therapeutic strategies.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  cell adhesion; cell-surface protein; matrix metalloproteinase (MMP); shedding; tumor metastasis

Mesh:

Substances:

Year:  2017        PMID: 29046355      PMCID: PMC5733611          DOI: 10.1074/jbc.M117.796789

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  MANSC: a seven-cysteine-containing domain present in animal membrane and extracellular proteins.

Authors:  Jinhu Guo; Shuai Chen; Chaoqun Huang; Li Chen; David J Studholme; Shouyuan Zhao; Long Yu
Journal:  Trends Biochem Sci       Date:  2004-04       Impact factor: 13.807

2.  Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity.

Authors:  Roman Szabo; John P Hobson; Karin List; Alfredo Molinolo; Chen-Yong Lin; Thomas H Bugge
Journal:  J Biol Chem       Date:  2008-08-19       Impact factor: 5.157

3.  Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form.

Authors:  T Shimomura; K Denda; T Kawaguchi; K Matsumoto; K Miyazawa; N Kitamura
Journal:  J Biochem       Date:  1999-11       Impact factor: 3.387

4.  Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.

Authors:  Daniel Kirchhofer; Mark Peek; Michael T Lipari; Karen Billeci; Bin Fan; Paul Moran
Journal:  FEBS Lett       Date:  2005-03-28       Impact factor: 4.124

5.  Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase.

Authors:  Takahiro Domoto; Takahisa Takino; Luyang Guo; Hiroshi Sato
Journal:  Cancer Sci       Date:  2011-12-28       Impact factor: 6.716

6.  Strong homophilic interactions of the Ig-like domains of polycystin-1, the protein product of an autosomal dominant polycystic kidney disease gene, PKD1.

Authors:  O Ibraghimov-Beskrovnaya; N O Bukanov; L C Donohue; W R Dackowski; K W Klinger; G M Landes
Journal:  Hum Mol Genet       Date:  2000-07-01       Impact factor: 6.150

7.  Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa.

Authors:  H Itoh; H Kataoka; M Tomita; R Hamasuna; Y Nawa; N Kitamura; M Koono
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-04       Impact factor: 4.052

8.  Identification of amino acid residues of the matrix metalloproteinase-2 essential for its selective inhibition by beta-amyloid precursor protein-derived inhibitor.

Authors:  Shouichi Higashi; Kaoru Miyazaki
Journal:  J Biol Chem       Date:  2008-01-31       Impact factor: 5.157

9.  Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases.

Authors:  Haixia Cheng; Tsuyoshi Fukushima; Nobuyasu Takahashi; Hiroyuki Tanaka; Hiroaki Kataoka
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

10.  Expression of matrilysin in vascular endothelial cells adjacent to matrilysin-producing tumors.

Authors:  Y Nagashima; S Hasegawa; N Koshikawa; A Taki; Y Ichikawa; H Kitamura; K Misugi; Y Kihira; Y Matuo; H Yasumitsu; K Miyazaki
Journal:  Int J Cancer       Date:  1997-07-29       Impact factor: 7.396

View more
  7 in total

Review 1.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

2.  Prognostic significance of GAD1 overexpression in patients with resected lung adenocarcinoma.

Authors:  Mitsuhiro Tsuboi; Kazuya Kondo; Kiyoshi Masuda; Shoichiro Tange; Koichiro Kajiura; Tomohiro Kohmoto; Hiromitsu Takizawa; Issei Imoto; Akira Tangoku
Journal:  Cancer Med       Date:  2019-06-17       Impact factor: 4.452

3.  Insufficiency of hepatocyte growth factor activator inhibitor-1 confers lymphatic invasion of tongue carcinoma cells.

Authors:  Aya Izumi; Koji Yamamoto; Makiko Kawaguchi; Fumiki Yamashita; Tsuyoshi Fukushima; Takumi Kiwaki; Hiroyuki Tanaka; Yoshihiro Yamashita; Hiroaki Kataoka
Journal:  Cancer Sci       Date:  2022-04-12       Impact factor: 6.518

4.  The effect of tubeimoside-1 on the proliferation, metastasis and apoptosis of oral squamous cell carcinoma in vitro.

Authors:  Tingting Wu; Hongjuan Cui; Yamei Xu; Quangao Du; Erhu Zhao; Jiangjun Cao; Ling Nie; Gang Fu; Aishu Ren
Journal:  Onco Targets Ther       Date:  2018-07-10       Impact factor: 4.147

Review 5.  Hepatocyte Growth Factor Activator: A Proteinase Linking Tissue Injury with Repair.

Authors:  Tsuyoshi Fukushima; Shuichiro Uchiyama; Hiroyuki Tanaka; Hiroaki Kataoka
Journal:  Int J Mol Sci       Date:  2018-11-01       Impact factor: 5.923

Review 6.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

7.  MMP-7 derived peptides with MHC class-I binding motifs from canine mammary tumor tissue elicit strong antigen-specific T-cell responses in BALB/c mice.

Authors:  Pavan Kumar Yadav; Shishir Kumar Gupta; Saroj Kumar; Mayukh Ghosh; Brijesh Singh Yadav; Dinesh Kumar; Ajay Kumar; Mohini Saini; Meena Kataria
Journal:  Mol Cell Biochem       Date:  2020-09-24       Impact factor: 3.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.